NSB Shares NeuroScientific Biopharmaceuticals Limited
ASX · ASXLast in our picks 2026-10-10 — not in the current list; analysis below is from that screen
Crohn’s disease access-program momentum supports progression toward a Phase 2 trial.
Signal breakdown
- ▸Fourth patient treated and trial-support partner appointed for planned Phase 2.
- ▾Below 50-day MA (-5.89%)
- ▾Near 52-week low (2.4% of range)
Is NSB a buy right now?
Trend: NSB is trading below the 50-day average (-13.33%), RSI 28 — oversold territory, with a 3-month return of -13.33%.
Valuation & quality: NeuroScientific Biopharmaceuticals Limited trades on price-to-book 1.37; fundamentals show net margin 0.0%, return on equity -29.7%, revenue growth 87.6% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$0.43 (+726.9% vs the last close; range A$0.43 – A$0.43), consensus rating “none”.
Our screen: WATCH (score 0) — Crohn’s disease access-program momentum supports progression toward a Phase 2 trial.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -10.00% | -33.30% | +0.00% | +0.00% | +0.00% | -16.70% |
Fundamentals
Analyst price target
Technical signals
About NeuroScientific Biopharmaceuticals Limited
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.